OptimizeRx Co. (NASDAQ:OPRX) Stake Lifted by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its position in shares of OptimizeRx Co. (NASDAQ:OPRX) by 189.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 3,690 shares of the company’s stock after buying an additional 2,414 shares during the quarter. BNP Paribas Financial Markets’ holdings in OptimizeRx were worth $28,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in OptimizeRx by 9.9% in the second quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock worth $1,117,000 after acquiring an additional 10,041 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of OptimizeRx in the 2nd quarter worth approximately $25,000. Legato Capital Management LLC lifted its stake in OptimizeRx by 74.0% during the second quarter. Legato Capital Management LLC now owns 59,693 shares of the company’s stock valued at $597,000 after purchasing an additional 25,377 shares during the last quarter. Rhumbline Advisers boosted its holdings in OptimizeRx by 9.2% during the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock worth $315,000 after buying an additional 2,658 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its holdings in OptimizeRx by 23.5% during the second quarter. Rice Hall James & Associates LLC now owns 496,135 shares of the company’s stock worth $4,961,000 after buying an additional 94,253 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at OptimizeRx

In related news, CEO William J. Febbo bought 20,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the transaction, the chief executive officer now directly owns 601,253 shares in the company, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.10% of the company’s stock.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $4.91 on Friday. The stock’s fifty day simple moving average is $5.41 and its 200-day simple moving average is $7.87. The company has a market capitalization of $90.45 million, a price-to-earnings ratio of -3.69 and a beta of 1.34. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $16.65.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Roth Mkm reaffirmed a “buy” rating and issued a $16.00 price target (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Barclays cut their target price on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 14th. Royal Bank of Canada decreased their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. JMP Securities dropped their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.71.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.